FU Hua,WEI Ying,LI Sha,et al.Effect of CyberKnife radiotherapy on peripheral blood lymphocytes of liver cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(01):73-75.
FU Hua,WEI Ying,LI Sha,et al.Effect of CyberKnife radiotherapy on peripheral blood lymphocytes of liver cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(01):73-75. DOI: 10.11659/jjssx.02E023021.
Effect of CyberKnife radiotherapy on peripheral blood lymphocytes of liver cancer
To explore the effects of different fractionation doses,fractionation methods,and other related parameters on the peripheral blood lymphocyte count of patients with liver cancer receiving CyberKnife radiotherapy.
Methods
2
The clinical data of 90 patients with liver cancer receiving CyberKnife radiotherapy in our hospital were retrospectively analyzed. The peripheral blood lymphocyte counts of patients 1 week before CyberKnife radiotherapy and 1 week,1 month and 3 months after treatment were determined. The effects of different prescribed doses,fractionation doses and numbers of fractionations on the peripheral blood lymphocyte count were analyzed.
Results
2
The peripheral blood lymphocyte counts of patients with different prescribed doses,fractionation doses and fractionation methods after CyberKnife treatment decreased to varying degrees compared with those 1 week before treatment (
P
<
0.05). The peripheral blood lymphocyte counts of patients in the groups with ≤5 fractionations and fractionation dose
>
7 Gy were significantly higher than those of patients in the groups with
>
5 fractionations and the fractionation dose≤7 Gy,respectively (
P
<
0.05). There was no significant difference in peripheral blood lymphocyte counts between patients with different prescribed doses before and after CyberKnife treatment (
P
>
0.05).
Conclusion
2
CyberKnife in the treatment of liver cancer with ≤5 ractionations and a fractionation dose of >7 Gy is more beneficial to alleviate the decrease of lymphocyte count caused by Cyberknife treatment.
Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA:A Cancer J Clin,2015,65(2):87-108.doi:10.3322/caac.21262http://dx.doi.org/10.3322/caac.21262.
Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA:A Cancer J Clin,2016,66(2):115-132.doi:10.3322/caac.21338http://dx.doi.org/10.3322/caac.21338.
Takeda A,Sanuki N,Tsurugai Y,et al.Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation[J].Cancer,2016,122(13):2041-2049.doi:10.1002/cncr. 30008http://dx.doi.org/10.1002/cncr.30008.
Long J,Bai Y,Yang X,et al. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma[J].Cancer Cell Int,2019,19:90.doi:10.1186/s12935-019-0817-yhttp://dx.doi.org/10.1186/s12935-019-0817-y.
Michael D. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract[J].Front Immunol,2017,8:1547.doi:10.3389/fimmu.2017.01547http://dx.doi.org/10.3389/fimmu.2017.01547.
Kuol N,Stojanovska L,Nurgali K,et al.PD-1/PD-L1 in disease[J].Immunotherapy,2018,10(2):149-160.doi:10.2217/imt-2017-0120http://dx.doi.org/10.2217/imt-2017-0120.
Zheng X,Hu Y,Yao C,et al.The paradoxical role of tumor-infiltrating immune cells in lung cancer[J].Intractable Rare Dis Res,2017,6(4):234-241.doi:10.5582/irdr.2017.01059http://dx.doi.org/10.5582/irdr.2017.01059.
Talebian Yazdi M,van Riet S,van Schadewijk A,et al.The positive prognostic effect of stromal CD8+ tumor-infltrating T cells is restrained by the expression of HLAE in non-small cell lung carcinoma[J].Oncotarget,2016,7(3):3477-3488.doi:10.18632/oncotarget.6506http://dx.doi.org/10.18632/oncotarget.6506.
Thomas PD,Kahn M.Kat3 coactivators in somatic stem cells and cancer stem cells:biological roles,evolution,and pharmacologic manipulation[J]. Cell Biol Toxicol,2016,32(1):61-81.doi:10.1007/s10565-016-9318-0http://dx.doi.org/10.1007/s10565-016-9318-0.
Wild AT,Herman JM,Dholakia AS.Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer[J].Int J Radiat Oncol Biol Phys,2016,94(3):571-579.doi:10.1016/ j.ijrobp.2015.11.260http://dx.doi.org/10.1016/j.ijrobp.2015.11.260.
Crocenzi T,Cottam B,Newll P,et al.A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma[J].J Immunother Cancer,2016,4: 45.doi: 10.1186/s40425-016-0149-6http://dx.doi.org/10.1186/s40425-016-0149-6.
Brown J,Carlson D,Brenner D,et al.The tumor radiobiology of SRS and SBRT:are more than the 5 Rs involved?[J].Int J Radiat Oncol Biol Phys,2014,88(2):254-262.doi:10.1016/j.ijrobp. 2013.07.022http://dx.doi.org/10.1016/j.ijrobp.2013.07.022.
Greten TF,Sangro B.Targets for immunotherapy of liver cancer[J].J Hepatol,2017,68(1):157-166.doi:10.1016/j.jhep.2017.09.007http://dx.doi.org/10.1016/j.jhep.2017.09.007.
Cho Y,Park S, Byun HK,et al.Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2019,105(5):1065-1073.doi:10.1016/j.ijrobp.2019.08.047http://dx.doi.org/10.1016/j.ijrobp.2019.08.047.
Jiang X,Xu J, Liu M,et al.Adoptive CD8+ T cell therapy against cancer: challenges and opportunities[J].Cancer Lett,2019,462(10):23-32.doi:10.1016/j.canlet.2019.07.017http://dx.doi.org/10.1016/j.canlet.2019.07.017.
Bonta I,Isac JF,Meiri E,et al.Correlation between tumor mutation burden and response to immunotherapy[J].J Clin Oncol,2017,35(15_suppl):e14579.doi: 10.1200/JCO.2017.35.15_suppl.e14579http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.e14579.
Yau T,Kang YK,Kim TY,et al.Nivolumab (NIVO)+ipilimumab(IPI) combination therapy in patients(pts) with advanced hepatocellular carcinoma (aHCC):results from CheckMate040[J].J Clin Oncol,2019,37(15_suppl):4012. doi: 10.1200/JCO.2019.37.15_suppl.4012http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4012.
Deng L,Liang H,Burnette B,et al.Irradiation and anti-PD-L1 treatment synergistically promote anti-tumor immunity in mice[J].J Clin Invest,2014,124(2):687-695.doi:10.1172/JCI67313http://dx.doi.org/10.1172/JCI67313.